Inactive Instrument

Elite Pharmaceuticals, Inc. Share Price Other OTC

Equities

ELTP

US28659T2006

Pharmaceuticals

Sales 2022 32.26M 2.57B Sales 2023 34.16M 2.72B Capitalization 29.4M 2.35B
Net income 2022 8M 638M Net income 2023 3M 239M EV / Sales 2022 0.92 x
Net cash position 2022 5.75M 459M Net cash position 2023 3.94M 315M EV / Sales 2023 0.75 x
P/E ratio 2022
4.73 x
P/E ratio 2023
9.34 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 77.76%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 63 31/07/13
Director of Finance/CFO 59 30/06/09
President 69 31/10/02
Members of the board TitleAgeSince
Director/Board Member 68 22/10/09
Director/Board Member 93 31/03/05
Director/Board Member 76 27/04/16
More insiders
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Phendimetrazine Tartrate 35mg tablets, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
More about the company